Every 8-K that ProMIS Neurosciences Inc. (PMN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMN filings page.
ProMIS Neurosciences Inc., a clinical-stage biotechnology company focused on antibody therapeutics for neurodegenerative diseases, reported second quarter 2026 results and updated progress on its lead Alzheimer’s candidate PMN310. The company highlighted blinded six-month interim safety and biomarker data from PRECISE-AD, its Phase 1b trial in early Alzheimer’s disease, noting that across 136 safety‑evaluable participants and all APOE genotypes, no cases of ARIA‑E were observed. The blinded analysis also showed early, directionally consistent changes in plasma pTau217 and CSF MTBR‑tau243.
Management stated that PMN310 targets toxic amyloid‑beta oligomers while avoiding plaque and may therefore reduce ARIA risk and potentially improve efficacy compared with plaque‑directed antibodies. Twelve‑month unblinded topline results from PRECISE‑AD, including cognitive outcomes, are expected in the first quarter of 2027. ProMIS ended June 30, 2026 with $53.4 million in cash and short‑term investments and reported total current assets of $56.7 million and shareholders’ equity of $49.4 million, which management believes provide runway through 2027. For the quarter, operating expenses were $12.3 million and the net loss was $11.7 million, compared with $10.2 million and $10.1 million respectively a year earlier.
ProMIS Neurosciences Inc. reported blinded six-month interim safety and biomarker data from PRECISE-AD, its Phase 1b trial of PMN310 in early Alzheimer’s disease. In 136 patients, PMN310 showed a favorable safety profile across all genotypes with no ARIA-E cases observed as of the data cutoff, and ARIA-H tracking background rates.
The interim readout also showed early, directionally consistent movement in disease-relevant biomarkers, including plasma pTau217 and CSF MTBR-tau243, suggesting target engagement, while the study remains blinded. PRECISE-AD has enrolled 144 participants receiving multiple intravenous doses of 5, 10, or 20 mg/kg for 12 months, with topline 12-month results expected in the first quarter of 2027. PMN310 is a humanized IgG1 antibody designed to selectively target toxic amyloid-beta oligomers and was granted FDA Fast Track Designation in July 2025.
ProMIS Neurosciences Inc. reported results of its 2026 annual meeting, where shareholders approved an amendment to the 2025 Stock Option and Incentive Plan to increase the shares available for issuance by 900,000 Common Shares. Seven director nominees were elected, each receiving more than 4.1 million votes for, with broker non-votes of 614,643.
Shareholder participation was moderate, with 4,762,024 Common Shares, or about 53.1% of the 8,967,693 shares outstanding as of the record date, present or represented by proxy. Shareholders also ratified Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
ProMIS Neurosciences Inc. reported first quarter 2026 results and highlighted progress in its Alzheimer’s program PMN310. The company closed a financing of up to $175 million, contributing to cash of $63,814,345 and total assets of $67,411,571 as of March 31, 2026, compared with $9,182,421 a year earlier. Shareholders' equity improved to $60,717,572 from a deficit of $(1,258,592).
For the quarter, research and development expenses were $6,971,005 and general and administrative expenses were $1,673,890, leading to a net loss of $8,244,372, or $(1.26) per share. The Phase 1b PRECISE-AD trial of PMN310 in early Alzheimer’s disease is fully enrolled, with a blinded 6‑month interim analysis anticipated in early Q3 2026 and topline data expected in early 2027.
ProMIS Neurosciences Inc. reported a 2025 net loss of $39.7 million, driven mainly by higher research and development spending of $33.4 million as it advanced its PRECISE-AD Phase 1b Alzheimer’s trial, after posting net income of $2.8 million in 2024.
Cash was $6.1 million as of December 31, 2025, with total assets of $9.2 million and a shareholders’ deficit of $1.3 million, reflecting increased accrued liabilities. The company subsequently closed a financing of up to $175 million, including $75 million up front and additional proceeds tied to future warrant exercises, which it expects to fund operations through 2027.
The PRECISE-AD Phase 1b trial of lead antibody PMN310 in Alzheimer’s disease was fully enrolled with 144 patients in December 2025. Six-month assessments and a blinded interim analysis are expected in mid to early Q3 2026, with unblinded top-line data anticipated in early 2027. PMN310 has Fast Track designation from the U.S. Food and Drug Administration and has shown a favorable safety profile to date with no treatment-related serious adverse events reported.
ProMIS Neurosciences Inc. entered into a private financing with accredited investors to raise approximately $75 million in gross proceeds through a combination of common shares and warrants. The final closing is expected on February 3, 2026.
The company agreed to sell 6,815,296 common shares, 100,000 pre-funded warrants and common share purchase warrants for 6,915,296 shares. Common shares were priced at $10.77 and $12.13 per share for certain affiliates and insiders, with warrants exercisable at $14.40. If all warrants are exercised for cash, the company may receive up to an additional approximately $100 million.
ProMIS Neurosciences Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq notified the company in writing that it now meets the $1.00 per share bid price rule and that the matter is closed.
The company had previously received a deficiency notice on January 8, 2025 after its common shares traded below $1.00 for 30 consecutive business days and was given up to two 180-day grace periods, extending to December 29, 2025. Its closing bid price was at least $1.00 for 10 consecutive business days from November 28, 2025 to December 11, 2025, which restored compliance with the bid price rule.
ProMIS Neurosciences Inc. (PMN) is implementing a reverse stock split of its common shares at a ratio of one-for-twenty-five. Effective as of 12:01 a.m. Eastern Time on November 28, 2025, every 25 issued and outstanding common shares will be automatically reclassified into one new common share, with no action required from shareholders.
The company is making proportional adjustments to equity incentive plan awards, stock options, other equity securities and all outstanding warrants, including both the number of shares issuable and the applicable exercise prices. The reverse split does not change the number of authorized common shares or their par value. No fractional shares will be issued; instead, shareholders entitled to a fractional share will receive cash in lieu of that fraction. Trading on The Nasdaq Capital Market will begin on a split-adjusted basis on November 28, 2025 under the existing symbol PMN, with a new CUSIP number 74346M505.
ProMIS Neurosciences Inc. reported the results of a special shareholder meeting held on November 17, 2025. Shareholders voted on a proposal to authorize a share consolidation of the company’s common shares at a ratio ranging from one-for-five up to one-for-twenty-five, with the exact ratio and timing within one year left to the Board of Directors’ discretion. Of the 53,811,110 common shares outstanding as of the record date, 24,328,153 shares, or about 45.21%, were present or represented by proxy.
The share consolidation proposal received 21,331,321 votes for, 2,939,187 votes against, and 57,645 abstentions, indicating strong support among participating shareholders. A second proposal, allowing adjournment of the meeting to solicit additional proxies if needed, also passed with 22,256,277 votes for, 1,786,586 votes against, and 285,290 abstentions, although the primary consolidation proposal was already approved.
ProMIS Neurosciences Inc. filed a Form 8-K to furnish its latest financial update. The company reported that a press release detailing its financial condition and results for the three and nine months ended September 30, 2025 has been made available. The release is posted on the company’s website under Investors/Financial Results and is included as Exhibit 99.1.
The filing lists the company’s common shares trading on The Nasdaq Capital Market under the symbol PMN. The press release is dated November 12, 2025 and is incorporated by reference under Item 2.02 (Results of Operations and Financial Condition).
ProMIS Neurosciences (PMN) appointed Slanix Paul Alex, Pharm.D., to its Board of Directors effective October 22, 2025. The Board determined he is independent under Nasdaq listing standards, and committee compositions remain unchanged. Dr. Alex is President and Portfolio Manager for the Public Equity strategy at Ally Bridge Group, with prior investing and research roles at Tri Locum Partners, Consonance Capital, RBC, and Credit Suisse. He holds a Pharm.D. from St. John’s University and is a licensed pharmacist.
Under the company’s non-employee director compensation policy, Dr. Alex received an option to purchase 40,000 common shares, vesting 25% at grant with the balance vesting ratably over 36 months, and an annual cash fee of $40,000. Beginning with the 2026 annual meeting, he will be eligible for an additional option to purchase 20,000 shares each year, vesting on the earlier of the one-year anniversary or the next annual meeting. Per Ally Bridge Group’s governance policy, his equity awards and cash compensation are attributed to Ally Bridge MedAlpha Master Fund L.P.
ProMIS Neurosciences Inc. updated the employment terms of its Chief Scientific Officer, Dr. Neil Cashman, through an Amended and Restated Employment Agreement effective September 26, 2025. Dr. Cashman will remain on the board and continue in his role as Chief Scientific Officer.
The amended agreement sets an annual base salary of $500,000 CAD and an annual discretionary bonus targeted at 35% of base salary. Dr. Cashman received an option to purchase 165,000 common shares at Fair Market Value on the grant date, vesting 25% after one year and the balance in equal monthly installments over thirty-six months.
He is entitled to 9 months of salary and continued benefits if terminated without cause, and to 9 months of salary, accelerated vesting of time-based equity awards, and continued benefits in connection with a change in control. The company states there are no family relationships or related-party transactions requiring disclosure.
ProMIS Neurosciences Inc. reported that an independent Data and Safety Monitoring Board for its ongoing PRECISE-AD Phase 1b trial has unanimously recommended proceeding to the third and final dose-escalation cohort of PMN310, its lead therapeutic candidate for Alzheimer’s disease. The recommendation followed a review of safety data through Cohort 2, which is now fully enrolled, with no cases of amyloid-related imaging abnormalities observed so far.
The company has begun enrolling patients in Cohort 3 and remains on track to report 6‑month interim data in the second quarter of 2026 and final top-line results in the fourth quarter of 2026, according to the disclosure.
ProMIS Neurosciences Inc. entered into an at-the-market offering agreement that allows it to sell common shares with an aggregate offering price of up to $17,988,524 through H.C. Wainwright & Co. as sales agent. Any sales will be made under a Form S-3 shelf registration statement and related prospectus materials, and no shares may be sold until the registration statement is declared effective by the SEC.
The agent may sell shares on Nasdaq or other markets using customary at-the-market methods and will receive a commission of up to 3% of the gross sales proceeds. The agreement does not obligate the agent to sell a specific amount of shares, and there is no escrow or similar arrangement for proceeds. Legal opinions from McMillan LLP regarding the issuance and sale of the shares are filed as exhibits.
ProMIS Neurosciences Inc. filed a Form 8-K announcing it issued a press release reporting its financial condition and results for the three and six months ended June 30, 2025. The filing states the press release is available on the company's website under Investors/Financial Results and that a copy is furnished as Exhibit 99.1 to the report. The 8-K identifies the company as a Nasdaq-listed registrant trading as PMN on The Nasdaq Capital Market and indicates the registrant has the status of an emerging growth company.
The filing itself does not include the financial statements or numerical results; investors are directed to the press release (Exhibit 99.1) for the detailed financial figures and discussion of the companys performance for the reported periods.
On 21 Jul 2025 ProMIS Neurosciences (PMN) filed an 8-K disclosing two material items.
- ATM program terminated: The Company and BTIG mutually ended the US$25 m at-the-market agreement first signed 5 Jan 2024. Only 75,862 shares were sold for gross proceeds of US$190,274, leaving US$24.8 m unused. No termination penalties apply and no further shares will be issued under this facility.
- Pipeline progress: The FDA granted Fast Track Designation to PMN310, ProMIS’s lead monoclonal antibody for Alzheimer’s disease. A Data & Safety Monitoring Board has authorised escalation to the 10 mg/kg cohort in the ongoing Phase 1b trial, and, as of 21 Jul 2025, no amyloid-related imaging abnormalities (ARIA) have been observed.
The filing contains no financial results, but it removes potential equity dilution from the ATM, while regulatory momentum for PMN310 could shorten the development timeline.